{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,6,22]],"date-time":"2026-06-22T23:27:26Z","timestamp":1782170846542,"version":"3.54.5"},"reference-count":100,"publisher":"Elsevier BV","issue":"1","license":[{"start":{"date-parts":[[2024,1,1]],"date-time":"2024-01-01T00:00:00Z","timestamp":1704067200000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/tdm\/userlicense\/1.0\/"},{"start":{"date-parts":[[2024,1,1]],"date-time":"2024-01-01T00:00:00Z","timestamp":1704067200000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/legal\/tdmrep-license"},{"start":{"date-parts":[[2023,10,3]],"date-time":"2023-10-03T00:00:00Z","timestamp":1696291200000},"content-version":"vor","delay-in-days":0,"URL":"http:\/\/creativecommons.org\/licenses\/by-nc\/4.0\/"}],"content-domain":{"domain":["clinicalkey.com","clinicalkey.com.au","clinicalkey.es","clinicalkey.fr","clinicalkey.jp","elsevier.com","sciencedirect.com"],"crossmark-restriction":true},"short-container-title":["Current Problems in Cardiology"],"published-print":{"date-parts":[[2024,1]]},"DOI":"10.1016\/j.cpcardiol.2023.102127","type":"journal-article","created":{"date-parts":[[2023,10,5]],"date-time":"2023-10-05T05:15:00Z","timestamp":1696482900000},"page":"102127","update-policy":"https:\/\/doi.org\/10.1016\/elsevier_cm_policy","source":"Crossref","is-referenced-by-count":12,"special_numbering":"PC","title":["Coagulation Disorders and Thrombotic Complications in Heart Failure With Preserved Ejection Fraction"],"prefix":"10.1016","volume":"49","author":[{"ORCID":"https:\/\/orcid.org\/0009-0002-0116-9919","authenticated-orcid":false,"given":"Kacper","family":"Karaban","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Dorota","family":"S\u0142upik","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Aleksandra","family":"Reda","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Magdalena","family":"Gajewska","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Bartosz","family":"Rolek","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Josip A.","family":"Borovac","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Panteleimon E.","family":"Papakonstantinou","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Dario","family":"Bongiovanni","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Hanne","family":"Ehrlinder","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"William A.E.","family":"Parker","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Aleksander","family":"Siniarski","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0001-5083-7587","authenticated-orcid":false,"given":"Aleksandra","family":"G\u0105secka","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"78","reference":[{"key":"10.1016\/j.cpcardiol.2023.102127_bib0001","doi-asserted-by":"crossref","unstructured":"TA M, M M, M A, et al. 2021 ESC Guidelines for the diagnosis and treatment of acute and chronic heart failure. Eur Heart J. 2021;42:3599-3726.","DOI":"10.1093\/eurheartj\/ehab368"},{"key":"10.1016\/j.cpcardiol.2023.102127_bib0002","doi-asserted-by":"crossref","first-page":"759","DOI":"10.1016\/S0140-6736(03)14282-1","article-title":"Effects of candesartan on mortality and morbidity in patients with chronic heart failure: The CHARM-overall programme","volume":"362","author":"Pfeffer","year":"2003","journal-title":"Lancet"},{"key":"10.1016\/j.cpcardiol.2023.102127_bib0003","doi-asserted-by":"crossref","DOI":"10.1016\/S0140-6736(03)14285-7","article-title":"Effects of candesartan in patients with chronic heart failure and preserved left-ventricular ejection fraction: The CHARM-preserved trial","volume":"362","author":"Yusuf","year":"2003","journal-title":"Lancet"},{"key":"10.1016\/j.cpcardiol.2023.102127_bib0004","doi-asserted-by":"crossref","DOI":"10.1056\/NEJMoa0805450","article-title":"Irbesartan in patients with heart failure and preserved ejection fraction","volume":"359","author":"Massie","year":"2008","journal-title":"N Engl J Med"},{"key":"10.1016\/j.cpcardiol.2023.102127_bib0005","doi-asserted-by":"crossref","DOI":"10.1056\/NEJMoa1908655","article-title":"Angiotensin\u2013neprilysin inhibition in heart failure with preserved ejection fraction","volume":"381","author":"Solomon","year":"2019","journal-title":"N Engl J Med"},{"key":"10.1016\/j.cpcardiol.2023.102127_bib0006","first-page":"10","article-title":"Spironolactone for heart failure with preserved ejection fraction","volume":"370","author":"B","year":"2014","journal-title":"N Engl J Med"},{"key":"10.1016\/j.cpcardiol.2023.102127_bib0007","doi-asserted-by":"crossref","DOI":"10.1161\/CIRCULATIONAHA.106.628347","article-title":"Effects of digoxin on morbidity and mortality in diastolic heart failure: the ancillary digitalis investigation group trial","volume":"114","author":"Ahmed","year":"2006","journal-title":"Circulation"},{"key":"10.1016\/j.cpcardiol.2023.102127_bib0008","doi-asserted-by":"crossref","first-page":"4370","DOI":"10.1002\/ehf2.13760","article-title":"A year in heart failure: an update of recent findings","volume":"8","author":"Stretti","year":"2021","journal-title":"ESC Heart Fail"},{"key":"10.1016\/j.cpcardiol.2023.102127_bib0009","doi-asserted-by":"crossref","first-page":"342","DOI":"10.1007\/s00392-014-0788-x","article-title":"Sex differences in new-onset heart failure","volume":"104","author":"Meyer","year":"2015","journal-title":"Clin Res Cardiol"},{"key":"10.1016\/j.cpcardiol.2023.102127_bib0010","doi-asserted-by":"crossref","first-page":"1424","DOI":"10.1093\/eurheartj\/eht066","article-title":"Incidence and epidemiology of new onset heart failure with preserved vs. reduced ejection fraction in a community-based cohort: 11-year follow-up of PREVEND","volume":"34","author":"Brouwers","year":"2013","journal-title":"Eur Heart J"},{"key":"10.1016\/j.cpcardiol.2023.102127_bib0011","doi-asserted-by":"crossref","first-page":"413","DOI":"10.1016\/S0002-9149(00)01393-X","article-title":"Importance of heart failure with preserved systolic function in patients >or\u202f=\u202f65 years of age. CHS Research Group. Cardiovascular Health Study","volume":"87","author":"Kitzman","year":"2001","journal-title":"Am J Cardiol"},{"key":"10.1016\/j.cpcardiol.2023.102127_bib0012","article-title":"Similarities and differences between HFmrEF and HFpEF","volume":"8","author":"Li","year":"2021","journal-title":"Front Cardiovasc Med"},{"key":"10.1016\/j.cpcardiol.2023.102127_bib0013","doi-asserted-by":"crossref","first-page":"1710","DOI":"10.1007\/s00380-022-02067-2","article-title":"Gender difference in heart failure with preserved ejection fraction: clinical profiles, examinations, and prognosis","volume":"37","author":"Sakai","year":"2022","journal-title":"Heart Vessels"},{"key":"10.1016\/j.cpcardiol.2023.102127_bib0014","doi-asserted-by":"crossref","first-page":"73","DOI":"10.1007\/s11936-020-00856-4","article-title":"Sex differences in HFpEF","volume":"22","author":"O'Kelly","year":"2020","journal-title":"Curr Treat Options Cardiol Med"},{"key":"10.1016\/j.cpcardiol.2023.102127_bib0015","doi-asserted-by":"crossref","first-page":"263","DOI":"10.1016\/j.jacc.2013.02.092","article-title":"A novel paradigm for heart failure with preserved ejection fraction: comorbidities drive myocardial dysfunction and remodeling through coronary microvascular endothelial inflammation","volume":"62","author":"Paulus","year":"2013","journal-title":"J Am Coll Cardiol"},{"key":"10.1016\/j.cpcardiol.2023.102127_bib0016","doi-asserted-by":"crossref","first-page":"507","DOI":"10.1038\/nrcardio.2014.83","article-title":"The pathophysiology of heart failure with preserved ejection fraction","volume":"11","author":"Borlaug","year":"2014","journal-title":"Nat Rev Cardiol"},{"key":"10.1016\/j.cpcardiol.2023.102127_bib0017","doi-asserted-by":"crossref","first-page":"32","DOI":"10.1016\/j.pharmthera.2016.10.019","article-title":"Atrial fibrillation in heart failure with preserved ejection fraction: insights into mechanisms and therapeutics","volume":"176","author":"Patel","year":"2017","journal-title":"Pharmacol Ther"},{"key":"10.1016\/j.cpcardiol.2023.102127_bib0018","doi-asserted-by":"crossref","first-page":"35","DOI":"10.1016\/j.jchf.2019.09.002","article-title":"HFpEF is the substrate for stroke in obesity and diabetes independent of atrial fibrillation","volume":"8","author":"Packer","year":"2020","journal-title":"JACC Heart Fail"},{"key":"10.1016\/j.cpcardiol.2023.102127_bib0019","doi-asserted-by":"crossref","first-page":"11853","DOI":"10.1038\/ncomms11853","article-title":"Endothelial to mesenchymal transition is common in atherosclerotic lesions and is associated with plaque instability","volume":"7","author":"Evrard","year":"2016","journal-title":"Nat Commun"},{"key":"10.1016\/j.cpcardiol.2023.102127_bib0020","doi-asserted-by":"crossref","first-page":"1163","DOI":"10.1161\/CIRCRESAHA.119.314813","article-title":"Endothelial-to-mesenchymal transition","volume":"124","author":"Bischoff","year":"2019","journal-title":"Circ Res"},{"key":"10.1016\/j.cpcardiol.2023.102127_bib0021","doi-asserted-by":"crossref","DOI":"10.1016\/j.phymed.2021.153633","article-title":"An herbal preparation ameliorates heart failure with preserved ejection fraction by alleviating microvascular endothelial inflammation and activating NO-cGMP-PKG pathway","volume":"91","author":"Huang","year":"2021","journal-title":"Phytomedicine"},{"key":"10.1016\/j.cpcardiol.2023.102127_bib0022","doi-asserted-by":"crossref","first-page":"1795","DOI":"10.1161\/CIRCULATIONAHA.111.040352","article-title":"Epithelial-to-mesenchymal and endothelial-to-mesenchymal transition: from cardiovascular development to disease","volume":"125","author":"Kovacic","year":"2012","journal-title":"Circulation"},{"key":"10.1016\/j.cpcardiol.2023.102127_bib0023","doi-asserted-by":"crossref","first-page":"136","DOI":"10.1016\/j.jacc.2017.05.029","article-title":"Arterial stiffening with exercise in patients with heart failure and preserved ejection fraction","volume":"70","author":"Reddy","year":"2017","journal-title":"J Am Coll Cardiol"},{"key":"10.1016\/j.cpcardiol.2023.102127_bib0024","doi-asserted-by":"crossref","first-page":"312","DOI":"10.1016\/j.jchf.2015.10.007","article-title":"Myocardial microvascular inflammatory endothelial activation in heart failure with preserved ejection fraction","volume":"4","author":"Franssen","year":"2016","journal-title":"JACC Heart Fail"},{"key":"10.1016\/j.cpcardiol.2023.102127_bib0025","doi-asserted-by":"crossref","first-page":"1347","DOI":"10.3389\/fphys.2019.01347","article-title":"Microvascular dysfunction in heart failure with preserved ejection fraction","volume":"10","author":"D'Amario","year":"2019","journal-title":"Front Physiol"},{"issue":"Part A","key":"10.1016\/j.cpcardiol.2023.102127_bib0026","doi-asserted-by":"crossref","first-page":"2817","DOI":"10.1016\/j.jacc.2014.03.034","article-title":"Implications of coronary artery disease in heart failure with preserved ejection fraction","volume":"63","author":"Hwang","year":"2014","journal-title":"J Am Coll Cardiol"},{"key":"10.1016\/j.cpcardiol.2023.102127_bib0027","doi-asserted-by":"crossref","first-page":"29","DOI":"10.1016\/j.jacc.2018.04.039","article-title":"Myocardial injury and cardiac reserve in patients with heart failure and preserved ejection fraction","volume":"72","author":"Obokata","year":"2018","journal-title":"J Am Coll Cardiol"},{"key":"10.1016\/j.cpcardiol.2023.102127_bib0028","doi-asserted-by":"crossref","first-page":"1472","DOI":"10.1002\/ejhf.630","article-title":"Right ventricular dysfunction in heart failure with preserved ejection fraction: a systematic review and meta-analysis","volume":"18","author":"Gorter","year":"2016","journal-title":"Eur J Heart Fail"},{"key":"10.1016\/j.cpcardiol.2023.102127_bib0029","doi-asserted-by":"crossref","first-page":"3439","DOI":"10.1093\/eurheartj\/ehy531","article-title":"Prevalence and correlates of coronary microvascular dysfunction in heart failure with preserved ejection fraction: PROMIS-HFpEF","volume":"39","author":"Shah","year":"2018","journal-title":"Eur Heart J"},{"key":"10.1016\/j.cpcardiol.2023.102127_bib0030","doi-asserted-by":"crossref","first-page":"255","DOI":"10.1007\/s10554-020-01953-y","article-title":"Prevalence of right ventricular dysfunction and prognostic significance in heart failure with preserved ejection fraction","volume":"37","author":"Kanagala","year":"2021","journal-title":"Int J Cardiovasc Imaging"},{"key":"10.1016\/j.cpcardiol.2023.102127_bib0031","doi-asserted-by":"crossref","first-page":"3452","DOI":"10.1093\/eurheartj\/ehu193","article-title":"Right heart dysfunction in heart failure with preserved ejection fraction","volume":"35","author":"Melenovsky","year":"2014","journal-title":"Eur Heart J"},{"key":"10.1016\/j.cpcardiol.2023.102127_bib0032","doi-asserted-by":"crossref","first-page":"689","DOI":"10.1093\/eurheartj\/ehy809","article-title":"Deterioration in right ventricular structure and function over time in patients with heart failure and preserved ejection fraction","volume":"40","author":"Obokata","year":"2019","journal-title":"Eur Heart J"},{"key":"10.1016\/j.cpcardiol.2023.102127_bib0033","doi-asserted-by":"crossref","first-page":"1598","DOI":"10.1161\/CIRCRESAHA.119.313572","article-title":"Heart failure with preserved ejection fraction in perspective","volume":"124","author":"Pfeffer","year":"2019","journal-title":"Circ Res"},{"key":"10.1016\/j.cpcardiol.2023.102127_bib0034","doi-asserted-by":"crossref","first-page":"1317","DOI":"10.3390\/jcm9051317","article-title":"Right ventricular free wall strain and congestive hepatopathy in patients with acute worsening of chronic heart failure: a CATSTAT-HF echo substudy","volume":"9","author":"Borovac","year":"2020","journal-title":"J Clin Med"},{"key":"10.1016\/j.cpcardiol.2023.102127_bib0035","doi-asserted-by":"crossref","first-page":"507","DOI":"10.1016\/j.hlc.2013.03.072","article-title":"Right ventricular function in left ventricular disease: pathophysiology and implications","volume":"22","author":"Schwarz","year":"2013","journal-title":"Heart Lung Circ"},{"key":"10.1016\/j.cpcardiol.2023.102127_bib0036","doi-asserted-by":"crossref","first-page":"523","DOI":"10.1161\/01.RES.58.4.523","article-title":"The effect of pericardiectomy on maximal oxygen consumption and maximal cardiac output in untrained dogs","volume":"58","author":"Stray-Gundersen","year":"1986","journal-title":"Circ Res"},{"key":"10.1016\/j.cpcardiol.2023.102127_bib0037","doi-asserted-by":"crossref","DOI":"10.1161\/CIRCHEARTFAILURE.119.006213","article-title":"Heart rate and heart failure with preserved ejection fraction: time to slow \u03b2-blocker use?","volume":"12","author":"Meyer","year":"2019","journal-title":"Circ Heart Fail"},{"key":"10.1016\/j.cpcardiol.2023.102127_bib0038","article-title":"Heart failure and the risk of left atrial thrombus formation in patients with atrial fibrillation or atrial flutter","volume":"9","author":"Wybraniec","year":"2022","journal-title":"ESC Heart Fail"},{"key":"10.1016\/j.cpcardiol.2023.102127_bib0039","doi-asserted-by":"crossref","first-page":"86","DOI":"10.1007\/s11906-019-0993-0","article-title":"Is heart failure with preserved ejection fraction a kidney disorder?","volume":"21","author":"Shah","year":"2019","journal-title":"Curr Hypertens Rep"},{"key":"10.1016\/j.cpcardiol.2023.102127_bib0040","doi-asserted-by":"crossref","DOI":"10.1161\/CIRCHEARTFAILURE.121.008372","article-title":"Endothelial-mesenchymal transition in heart failure with a preserved ejection fraction: insights into the cardiorenal syndrome","volume":"14","author":"Valero-Mu\u00f1oz","year":"2021","journal-title":"Circ Heart Fail"},{"key":"10.1016\/j.cpcardiol.2023.102127_bib0041","doi-asserted-by":"crossref","first-page":"1162","DOI":"10.1093\/ndt\/gfv009","article-title":"Chronic kidney disease and the risk of stroke: a systematic review and meta-analysis","volume":"30","author":"Masson","year":"2015","journal-title":"Nephrol Dial Transplant"},{"key":"10.1016\/j.cpcardiol.2023.102127_bib0042","doi-asserted-by":"crossref","first-page":"29","DOI":"10.1093\/ckj\/sfv136","article-title":"Modulation of stroke risk in chronic kidney disease","volume":"9","author":"Arnold","year":"2016","journal-title":"Clin Kidney J"},{"key":"10.1016\/j.cpcardiol.2023.102127_bib0043","doi-asserted-by":"crossref","first-page":"1304","DOI":"10.1016\/j.kint.2019.02.022","article-title":"Heart failure in chronic kidney disease: conclusions from a Kidney Disease: Improving Global Outcomes (KDIGO) controversies conference","volume":"95","author":"House","year":"2019","journal-title":"Kidney Int"},{"key":"10.1016\/j.cpcardiol.2023.102127_bib0044","doi-asserted-by":"crossref","first-page":"604","DOI":"10.1053\/j.ajkd.2013.10.013","article-title":"Risk of stroke in long-term dialysis patients compared with the general population","volume":"63","author":"Wang","year":"2014","journal-title":"Am J Kidney Dis"},{"key":"10.1016\/j.cpcardiol.2023.102127_bib0045","doi-asserted-by":"crossref","first-page":"374","DOI":"10.1016\/j.thromres.2008.03.024","article-title":"Hypercoagulability in chronic kidney disease is associated with coagulation activation but not endothelial function","volume":"123","author":"Adams","year":"2008","journal-title":"Thromb Res"},{"key":"10.1016\/j.cpcardiol.2023.102127_bib0046","doi-asserted-by":"crossref","first-page":"845","DOI":"10.1111\/jth.15653","article-title":"Evaluation of novel coagulation and platelet function assays in patients with chronic kidney disease","volume":"20","author":"Abdelmaguid","year":"2022","journal-title":"J Thromb Haemost"},{"key":"10.1016\/j.cpcardiol.2023.102127_bib0047","doi-asserted-by":"crossref","unstructured":"Huang MJ, Wei RB, Wang Y, et al. Blood coagulation system in patients with chronic kidney disease: a prospective observational study. BMJ Open. 2017;7:e014294.","DOI":"10.1136\/bmjopen-2016-014294"},{"key":"10.1016\/j.cpcardiol.2023.102127_bib0048","doi-asserted-by":"crossref","first-page":"111","DOI":"10.15420\/ecr.2019.11.1","article-title":"Hypertension and stroke: update on treatment","volume":"14","author":"Wajngarten","year":"2019","journal-title":"Eur Cardiol"},{"key":"10.1016\/j.cpcardiol.2023.102127_bib0049","doi-asserted-by":"crossref","first-page":"439","DOI":"10.1161\/CIRCRESAHA.116.308413","article-title":"Global burden of stroke","volume":"120","author":"Feigin","year":"2017","journal-title":"Circ Res"},{"key":"10.1016\/j.cpcardiol.2023.102127_bib0050","doi-asserted-by":"crossref","first-page":"933","DOI":"10.1007\/s11239-020-02342-x","article-title":"Inflammatory cytokines enhance procoagulant activity of platelets and endothelial cells through phosphatidylserine exposure in patients with essential hypertension","volume":"51","author":"Li","year":"2021","journal-title":"J Thromb Thrombolysis"},{"key":"10.1016\/j.cpcardiol.2023.102127_bib0051","doi-asserted-by":"crossref","first-page":"1236","DOI":"10.1161\/01.HYP.0000193538.20705.23","article-title":"The prothrombotic paradox of hypertension: role of the renin-angiotensin and kallikrein-kinin systems","volume":"46","author":"Dielis","year":"2005","journal-title":"Hypertension"},{"key":"10.1016\/j.cpcardiol.2023.102127_bib0052","doi-asserted-by":"crossref","first-page":"1383","DOI":"10.1056\/NEJMoa1313731","article-title":"Spironolactone for heart failure with preserved ejection fraction","volume":"370","author":"Pitt","year":"2014","journal-title":"N Engl J Med"},{"key":"10.1016\/j.cpcardiol.2023.102127_bib0053","doi-asserted-by":"crossref","first-page":"2456","DOI":"10.1056\/NEJMoa0805450","article-title":"Irbesartan in patients with heart failure and preserved ejection fraction","volume":"359","author":"Massie","year":"2008","journal-title":"N Engl J Med"},{"key":"10.1016\/j.cpcardiol.2023.102127_bib0054","doi-asserted-by":"crossref","first-page":"1609","DOI":"10.1056\/NEJMoa1908655","article-title":"Angiotensin-neprilysin inhibition in heart failure with preserved ejection fraction","volume":"381","author":"Solomon","year":"2019","journal-title":"N Engl J Med"},{"key":"10.1016\/j.cpcardiol.2023.102127_bib0055","doi-asserted-by":"crossref","first-page":"470","DOI":"10.1007\/s00059-004-2607-z","article-title":"Fibrinogen and fibrin clot structure in diabetes","volume":"29","author":"Dunn","year":"2004","journal-title":"Herz"},{"key":"10.1016\/j.cpcardiol.2023.102127_bib0056","doi-asserted-by":"crossref","first-page":"157","DOI":"10.1111\/j.1365-2796.2007.01824.x","article-title":"Diabetes mellitus as a prothrombotic condition","volume":"262","author":"Grant","year":"2007","journal-title":"J Intern Med"},{"key":"10.1016\/j.cpcardiol.2023.102127_bib0057","doi-asserted-by":"crossref","first-page":"191","DOI":"10.1186\/s12933-021-01372-w","article-title":"Hypofibrinolysis in type 2 diabetes and its clinical implications: from mechanisms to pharmacological modulation","volume":"20","author":"Bryk-Wi\u0105zania","year":"2021","journal-title":"Cardiovasc Diabetol"},{"key":"10.1016\/j.cpcardiol.2023.102127_bib0058","doi-asserted-by":"crossref","first-page":"2981","DOI":"10.1001\/jama.288.23.2981","volume":"288","year":"2002","journal-title":"JAMA"},{"key":"10.1016\/j.cpcardiol.2023.102127_bib0059","doi-asserted-by":"crossref","first-page":"2545","DOI":"10.1056\/NEJMoa0802743","article-title":"Effects of intensive glucose lowering in type 2 diabetes","volume":"358","author":"Gerstein","year":"2008","journal-title":"N Engl J Med"},{"key":"10.1016\/j.cpcardiol.2023.102127_bib0060","doi-asserted-by":"crossref","first-page":"2058","DOI":"10.1056\/NEJMoa042739","article-title":"Angiotensin-converting-enzyme inhibition in stable coronary artery disease","volume":"351","author":"Braunwald","year":"2004","journal-title":"N Engl J Med"},{"key":"10.1016\/j.cpcardiol.2023.102127_bib0061","doi-asserted-by":"crossref","first-page":"20","DOI":"10.1161\/CIRCULATIONAHA.117.028365","article-title":"Obese heart failure with preserved ejection fraction phenotype: from pariah to central player","volume":"136","author":"Kitzman","year":"2017","journal-title":"Circulation"},{"key":"10.1016\/j.cpcardiol.2023.102127_bib0062","doi-asserted-by":"crossref","DOI":"10.1371\/journal.pone.0099495","article-title":"Circulating levels of tumor necrosis factor-alpha receptor 2 are increased in heart failure with preserved ejection fraction relative to heart failure with reduced ejection fraction: evidence for a divergence in pathophysiology","volume":"9","author":"Putko","year":"2014","journal-title":"PLoS One"},{"key":"10.1016\/j.cpcardiol.2023.102127_bib0063","doi-asserted-by":"crossref","first-page":"27","DOI":"10.1111\/j.1467-789X.2011.00930.x","article-title":"Platelet activation in obesity and metabolic syndrome","volume":"13","author":"Santilli","year":"2012","journal-title":"Obes Rev"},{"key":"10.1016\/j.cpcardiol.2023.102127_bib0064","doi-asserted-by":"crossref","first-page":"759","DOI":"10.1111\/j.1538-7836.2010.03766.x","article-title":"Thrombin generation in morbid obesity: significant reduction after weight loss","volume":"8","author":"Ay","year":"2010","journal-title":"J Thromb Haemost"},{"key":"10.1016\/j.cpcardiol.2023.102127_bib0065","doi-asserted-by":"crossref","DOI":"10.3389\/fcvm.2021.743327","article-title":"The \u201cobesity paradox\u201d in patients with HFpEF with or without comorbid atrial fibrillation","volume":"8","author":"Guo","year":"2022","journal-title":"Front Cardiovasc Med"},{"key":"10.1016\/j.cpcardiol.2023.102127_bib0066","doi-asserted-by":"crossref","first-page":"698","DOI":"10.1016\/j.hlc.2020.10.010","article-title":"Meta-analysis of atrial fibrillation and outcomes in patients with heart failure and preserved ejection fraction","volume":"30","author":"Liu","year":"2021","journal-title":"Heart Lung Circ"},{"key":"10.1016\/j.cpcardiol.2023.102127_bib0067","doi-asserted-by":"crossref","first-page":"2478","DOI":"10.1093\/eurheartj\/ehw087","article-title":"Catheter ablation for atrial fibrillation is associated with lower incidence of stroke and death: data from Swedish health registries","volume":"37","author":"Friberg","year":"2016","journal-title":"Eur Heart J"},{"key":"10.1016\/j.cpcardiol.2023.102127_bib0068","doi-asserted-by":"crossref","DOI":"10.1371\/journal.pone.0186856","article-title":"The effects of rhythm control strategies versus rate control strategies for atrial fibrillation and atrial flutter: a systematic review with meta-analysis and trial sequential analysis","volume":"12","author":"Sethi","year":"2017","journal-title":"PLoS One"},{"key":"10.1016\/j.cpcardiol.2023.102127_bib0069","doi-asserted-by":"crossref","first-page":"41","DOI":"10.1016\/j.ahj.2015.11.016","article-title":"Body mass index and the risk of new-onset atrial fibrillation in middle-aged adults","volume":"173","author":"Berkovitch","year":"2016","journal-title":"Am Heart J"},{"key":"10.1016\/j.cpcardiol.2023.102127_bib0070","doi-asserted-by":"crossref","first-page":"1104","DOI":"10.1111\/jce.12199","article-title":"Association of atrial fibrosis quantified using LGE-MRI with atrial appendage thrombus and spontaneous contrast on transesophageal echocardiography in patients with atrial fibrillation","volume":"24","author":"Akoum","year":"2013","journal-title":"J Cardiovasc Electrophysiol"},{"key":"10.1016\/j.cpcardiol.2023.102127_bib0071","doi-asserted-by":"crossref","first-page":"62","DOI":"10.1161\/CIRCEP.107.754564","article-title":"Atrial remodeling and atrial fibrillation: mechanisms and implications","volume":"1","author":"Nattel","year":"2008","journal-title":"Circ Arrhythm Electrophysiol"},{"key":"10.1016\/j.cpcardiol.2023.102127_bib0072","doi-asserted-by":"crossref","first-page":"451","DOI":"10.1161\/CIRCHEARTFAILURE.112.000143","article-title":"Left ventricular systolic dysfunction, heart failure, and the risk of stroke and systemic embolism in patients with atrial fibrillation: insights from the ARISTOTLE trial","volume":"6","author":"McMurray","year":"2013","journal-title":"Circ Heart Fail"},{"key":"10.1016\/j.cpcardiol.2023.102127_bib0073","doi-asserted-by":"crossref","first-page":"667","DOI":"10.1161\/STROKEAHA.114.007140","article-title":"Relationship between degree of left ventricular dysfunction, symptom status, and risk of embolic events in patients with atrial fibrillation and heart failure","volume":"46","author":"Sandhu","year":"2015","journal-title":"Stroke"},{"key":"10.1016\/j.cpcardiol.2023.102127_bib0074","doi-asserted-by":"crossref","first-page":"2310","DOI":"10.1161\/CIRCULATIONAHA.113.008461","article-title":"Right ventricular function in heart failure with preserved ejection fraction: a community-based study","volume":"130","author":"Mohammed","year":"2014","journal-title":"Circulation"},{"key":"10.1016\/j.cpcardiol.2023.102127_bib0075","doi-asserted-by":"crossref","DOI":"10.1161\/CIRCHEARTFAILURE.122.010377","article-title":"Predicting stroke in heart failure and preserved ejection fraction without atrial fibrillation","volume":"16","author":"Kondo","year":"2023","journal-title":"Circ Heart Fail"},{"key":"10.1016\/j.cpcardiol.2023.102127_bib0076","doi-asserted-by":"crossref","DOI":"10.1080\/09537104.2023.2188965","article-title":"Mean platelet volume: a prognostic marker in heart failure with preserved ejection fraction","volume":"34","author":"Menghoum","year":"2023","journal-title":"Platelets"},{"key":"10.1016\/j.cpcardiol.2023.102127_bib0077","doi-asserted-by":"crossref","first-page":"18","DOI":"10.1186\/s12967-016-0774-3","article-title":"Combining patient proteomics and in vitro cardiomyocyte phenotype testing to identify potential mediators of heart failure with preserved ejection fraction","volume":"14","author":"Raphael","year":"2016","journal-title":"J Transl Med"},{"key":"10.1016\/j.cpcardiol.2023.102127_bib0078","doi-asserted-by":"crossref","first-page":"211","DOI":"10.1093\/eurjhf\/hfr172","article-title":"Stroke aetiology and predictors of outcome in patients with heart failure and acute stroke: a 10-year follow-up study","volume":"14","author":"Vemmos","year":"2012","journal-title":"Eur J Heart Fail"},{"key":"10.1016\/j.cpcardiol.2023.102127_bib0079","doi-asserted-by":"crossref","first-page":"155","DOI":"10.1016\/S0140-6736(09)60040-4","article-title":"Mechanisms of thrombogenesis in atrial fibrillation: Virchow's triad revisited","volume":"373","author":"Watson","year":"2009","journal-title":"Lancet"},{"key":"10.1016\/j.cpcardiol.2023.102127_bib0080","doi-asserted-by":"crossref","first-page":"e146","DOI":"10.1161\/CIR.0000000000000485","article-title":"Heart disease and stroke statistics-2017 update: a report from the American Heart Association","volume":"135","author":"Benjamin","year":"2017","journal-title":"Circulation"},{"key":"10.1016\/j.cpcardiol.2023.102127_bib0081","first-page":"742","article-title":"Risk of stroke in chronic heart failure patients with preserved ejection fraction, but without atrial fibrillation: analysis of the CHARM-Preserved and I-Preserve trials","volume":"38","author":"Abdul-Rahim","year":"2017","journal-title":"Eur Heart J"},{"key":"10.1016\/j.cpcardiol.2023.102127_bib0082","doi-asserted-by":"crossref","first-page":"1303","DOI":"10.1002\/ejhf.812","article-title":"High prevalence of subclinical cerebral infarction in patients with heart failure with preserved ejection fraction","volume":"19","author":"Cogswell","year":"2017","journal-title":"Eur J Heart Fail"},{"key":"10.1016\/j.cpcardiol.2023.102127_bib0083","doi-asserted-by":"crossref","DOI":"10.1161\/JAHA.121.024292","article-title":"Left atrial remodeling and stroke in patients with sinus rhythm and normal ejection fraction: ARIC-NCS","volume":"11","author":"Bianco","year":"2022","journal-title":"J Am Heart Assoc"},{"key":"10.1016\/j.cpcardiol.2023.102127_bib0084","doi-asserted-by":"crossref","first-page":"1283","DOI":"10.1016\/j.amjcard.2011.06.045","article-title":"Comparison of mortality and morbidity in patients with atrial fibrillation and heart failure with preserved versus decreased left ventricular ejection fraction","volume":"108","author":"Badheka","year":"2011","journal-title":"Am J Cardiol"},{"key":"10.1016\/j.cpcardiol.2023.102127_bib0085","doi-asserted-by":"crossref","first-page":"403","DOI":"10.1007\/s00380-017-1073-5","article-title":"Thromboembolisms in atrial fibrillation and heart failure patients with a preserved ejection fraction (HFpEF) compared to those with a reduced ejection fraction (HFrEF)","volume":"33","author":"Sobue","year":"2018","journal-title":"Heart Vessels"},{"key":"10.1016\/j.cpcardiol.2023.102127_bib0086","doi-asserted-by":"crossref","first-page":"660","DOI":"10.1016\/j.ijcard.2015.10.220","article-title":"Atrial fibrillation and heart failure due to reduced versus preserved ejection fraction: a systematic review and meta-analysis of death and adverse outcomes","volume":"203","author":"Kotecha","year":"2016","journal-title":"Int J Cardiol"},{"key":"10.1016\/j.cpcardiol.2023.102127_bib0087","doi-asserted-by":"crossref","first-page":"159","DOI":"10.1016\/j.jacc.2019.11.028","article-title":"Venous thromboembolism in heart failure patients: pathophysiology, predictability, prevention","volume":"75","author":"Goldhaber","year":"2020","journal-title":"J Am Coll Cardiol"},{"key":"10.1016\/j.cpcardiol.2023.102127_bib0088","doi-asserted-by":"crossref","first-page":"252","DOI":"10.1016\/j.amjmed.2010.10.014","article-title":"Venous thromboembolism in heart failure: preventable deaths during and after hospitalization","volume":"124","author":"Piazza","year":"2011","journal-title":"Am J Med"},{"key":"10.1016\/j.cpcardiol.2023.102127_bib0089","doi-asserted-by":"crossref","first-page":"148","DOI":"10.1016\/j.jacc.2019.10.058","article-title":"Incident heart failure and long-term risk for venous thromboembolism","volume":"75","author":"Fanola","year":"2020","journal-title":"J Am Coll Cardiol"},{"key":"10.1016\/j.cpcardiol.2023.102127_bib0090","doi-asserted-by":"crossref","first-page":"4061","DOI":"10.1002\/ehf2.13015","article-title":"Predictive value of heart failure with reduced versus preserved ejection fraction for outcome in pulmonary embolism","volume":"7","author":"Slobodan","year":"2020","journal-title":"ESC Heart Fail"},{"key":"10.1016\/j.cpcardiol.2023.102127_bib0091","doi-asserted-by":"crossref","first-page":"471","DOI":"10.1160\/TH16-08-0600","article-title":"Prognostic significance of tPA\/PAI-1 complex in patients with heart failure and preserved ejection fraction","volume":"117","author":"Winter","year":"2017","journal-title":"Thromb Haemost"},{"key":"10.1016\/j.cpcardiol.2023.102127_bib0092","doi-asserted-by":"crossref","first-page":"25","DOI":"10.1161\/CIRCHEARTFAILURE.114.001478","article-title":"Von Willebrand factor improves risk prediction in addition to N-terminal pro-B-type natriuretic peptide in patients referred to coronary angiography and signs and symptoms of heart failure and preserved ejection fraction","volume":"8","author":"Kleber","year":"2015","journal-title":"Circ Heart Fail"},{"key":"10.1016\/j.cpcardiol.2023.102127_bib0093","doi-asserted-by":"crossref","first-page":"c244","DOI":"10.1159\/000167872","article-title":"Endothelial activation markers in anemic non-dialysis chronic kidney disease patients","volume":"110","author":"Patel","year":"2008","journal-title":"Nephron Clin Pract"},{"key":"10.1016\/j.cpcardiol.2023.102127_bib0094","doi-asserted-by":"crossref","first-page":"380","DOI":"10.1055\/s-0038-1649589","article-title":"Associations of factor VIII and von Willebrand factor with age, race, sex, and risk factors for atherosclerosis. The Atherosclerosis Risk in Communities (ARIC) study","volume":"70","author":"Conlan","year":"1993","journal-title":"Thromb Haemost"},{"key":"10.1016\/j.cpcardiol.2023.102127_bib0095","doi-asserted-by":"crossref","first-page":"2496","DOI":"10.1016\/j.jacc.2010.12.033","article-title":"Plasma von Willebrand factor levels are an independent risk factor for adverse events including mortality and major bleeding in anticoagulated atrial fibrillation patients","volume":"57","author":"Rold\u00e1n","year":"2011","journal-title":"J Am Coll Cardiol"},{"key":"10.1016\/j.cpcardiol.2023.102127_bib0096","doi-asserted-by":"crossref","first-page":"223","DOI":"10.1016\/j.thromres.2004.12.007","article-title":"The complex between tPA and PAI-1: risk factor for myocardial infarction as studied in the SHEEP project","volume":"116","author":"Nordenhem","year":"2005","journal-title":"Thromb Res"},{"key":"10.1016\/j.cpcardiol.2023.102127_bib0097","doi-asserted-by":"crossref","first-page":"883","DOI":"10.1056\/NEJMoa1009638","article-title":"Rivaroxaban versus warfarin in nonvalvular atrial fibrillation","volume":"365","author":"Patel","year":"2011","journal-title":"N Engl J Med"},{"key":"10.1016\/j.cpcardiol.2023.102127_bib0098","doi-asserted-by":"crossref","first-page":"2093","DOI":"10.1056\/NEJMoa1310907","article-title":"Edoxaban versus warfarin in patients with atrial fibrillation","volume":"369","author":"Giugliano","year":"2013","journal-title":"N Engl J Med"},{"key":"10.1016\/j.cpcardiol.2023.102127_bib0099","doi-asserted-by":"crossref","DOI":"10.3389\/fcvm.2022.949726","article-title":"Non-vitamin K antagonist oral anticoagulants versus warfarin in atrial fibrillation patients with heart failure and preserved, mildly reduced, and reduced ejection fraction: a systemic review and meta-analysis","volume":"9","author":"Wulamiding","year":"2022","journal-title":"Front Cardiovasc Med"},{"key":"10.1016\/j.cpcardiol.2023.102127_bib0100","doi-asserted-by":"crossref","DOI":"10.1016\/j.cpcardiol.2023.101929","article-title":"Comment on: blood coagulation disorders in heart failure: from basic science to clinical perspectives","author":"Zain","year":"2023","journal-title":"Curr Probl Cardiol"}],"container-title":["Current Problems in Cardiology"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S0146280623005443?httpAccept=text\/xml","content-type":"text\/xml","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S0146280623005443?httpAccept=text\/plain","content-type":"text\/plain","content-version":"vor","intended-application":"text-mining"}],"deposited":{"date-parts":[[2025,9,27]],"date-time":"2025-09-27T02:27:27Z","timestamp":1758940047000},"score":1,"resource":{"primary":{"URL":"https:\/\/linkinghub.elsevier.com\/retrieve\/pii\/S0146280623005443"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2024,1]]},"references-count":100,"journal-issue":{"issue":"1","published-print":{"date-parts":[[2024,1]]}},"alternative-id":["S0146280623005443"],"URL":"https:\/\/doi.org\/10.1016\/j.cpcardiol.2023.102127","relation":{},"ISSN":["0146-2806"],"issn-type":[{"value":"0146-2806","type":"print"}],"subject":[],"published":{"date-parts":[[2024,1]]},"assertion":[{"value":"Elsevier","name":"publisher","label":"This article is maintained by"},{"value":"Coagulation Disorders and Thrombotic Complications in Heart Failure With Preserved Ejection Fraction","name":"articletitle","label":"Article Title"},{"value":"Current Problems in Cardiology","name":"journaltitle","label":"Journal Title"},{"value":"https:\/\/doi.org\/10.1016\/j.cpcardiol.2023.102127","name":"articlelink","label":"CrossRef DOI link to publisher maintained version"},{"value":"article","name":"content_type","label":"Content Type"},{"value":"\u00a9 2023 The Authors. Published by Elsevier Inc.","name":"copyright","label":"Copyright"}],"article-number":"102127"}}